Enterprise Value to EBITDA Ratio: Calidi Bio (CLDI)
Calidi Biotherapeutics (CLDI) is developing advanced methods for transporting stem cells to neoplasms for their destruction. This price chart on the page demonstrates an EV/EBITDA of 0.00. Business revenues will be based on the implementation of CLD-101 and CLD-201 systems. High FDA certification costs and strict patents create a powerful defensive barrier, ensuring the company maintains an exclusive position in the industry.
Summary analytical data breakdowns for calidibio.com (CLDI)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Calidi Biotherapeutics|CLDI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Calidi Biotherapeutics, Inc.|CLDI - Company Aggregate Debts|Debt to Book Capitalization Ratio Calidi Biotherapeutics|CLDI - Company Long-Term Debt|Company Short-Term Debts Calidi Biotherapeutics|Quick Ratio calidibio.com
- business earnings and investment ratios data:
CLDI - Company Profit|Projected Future Earnings Calidi Biotherapeutics|CLDI - Business Payback Period|Projected Price to Earnings Calidi Biotherapeutics, Inc.|CLDI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Calidi Biotherapeutics|CLDI - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Calidi Biotherapeutics|CLDI - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months calidibio.com|CLDI - Earnings per share growth rate in current year|Expected earnings per share growth for next year Calidi Biotherapeutics
Fundamental company analysis:CLDI (Calidi Bio)
The investment attractiveness of Calidi Biotherapeutics (CLDI) is based on the potential of oncolytic platforms currently in clinical trials without current profits. This metric compares the total enterprise value, accounting for debt load and operating income, revealing the company's dependence on external financing in the absence of its own cash flows. An analysis of historical EV/EBITDA values confirms that sharp spikes in the indicator here reflect a critical reduction in operating efficiency rather than market overheating.
Who Calidi Biotherapeutics competes with
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLS: EV/EBITDA Multiple|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|CTOR (Citius Oncology) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation HURA (TuHURA)|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRX|Champions Oncology Corp - EV/EBITDA Multiple|XBIT: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CVM: EV/EBITDA Multiple|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Company Value to EBITDA Artiva ARTV|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|Enterprise Value to Operating Income Before Depreciation Ratio VERU|EV/EBITDA Multiple TPST (Tempest Tx)|Business Value to Operating Income Before Depreciation XLO|Enochian BioSciences - EV/EBITDA Multiple|Company Value to EBITDA Mural Oncology plc|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OnKure Therapeutics - Business Value to Operating Income Before Depreciation|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|EV/EBITDA Multiple Curis Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|THAR: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ADVB (Advanced Biomed)|Genprex Inc. (GNPX) - Company Value to EBITDA|SBFM: Enterprise Value to EBITDA Ratio|XBIO - EV/EBITDA Multiple|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|PPBT: Enterprise Value to Operating Income Before Depreciation Ratio|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|Total Company Value to Operating Income Before Depreciation Ratio Ikena Oncology Inc. (IKNA)|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA (NAYA Biosciences Corp) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
